The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -6,008 | -12,640 |
| Depreciation | 427 | 881 |
| Foreign exchange (gain) loss | -1,202 | 3,365 |
| Share-based compensation expense | 24 | 3,436 |
| Income tax receivable | -83 | 0 |
| Accrued interest receivable | -30 | -220 |
| Prepaid expenses and other current assets | -254 | 281 |
| Accounts payable | -385 | -795 |
| Accrued expenses | 12 | -222 |
| Income tax payable | 102 | 57 |
| Net cash used in operating activities | -4,259 | -12,709 |
| Purchase of property and equipment | 110 | 145 |
| Net cash (used in) investing activities | -110 | -145 |
| Payment on convertible loan, third party | 0 | -10,000 |
| Payment on convertible loan, third party-Nonrelated Party | 0 | -250 |
| Proceeds from issuance of common stock under stock option plan | 0 | 0 |
| Net cash (used in) provided by financing activities | 0 | -10,250 |
| Effect of foreign exchange rate on cash and cash equivalents | -1,202 | 3,365 |
| Net change in cash and cash equivalents | -5,571 | -19,739 |
| Cash and cash equivalents at beginning of period | 172,677 | - |
| Cash and cash equivalents at end of period | 147,367 | - |
XBiotech Inc. (XBIT)
XBiotech Inc. (XBIT)